Literature DB >> 29713007

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Matthew Truong1, Thomas Frye1, Edward Messing1,2, Hiroshi Miyamoto3,4.   

Abstract

The Gleason scoring system is widely used for the grading and prognostication of prostate cancer. A Gleason pattern 4 subtype known as cribriform morphology has now been recognized as an aggressive and often lethal pattern of prostate cancer. The vast majority of published and ongoing prostate cancer studies still do not acknowledge the prognostic differences between various Gleason pattern 4 morphologies. As a result, current treatment recommendations are likely to be imprecise and not tailored towards patients who are most likely to die from the disease. Use of active surveillance for patients with Gleason score 3 + 4 prostate cancer has been suggested. However, the success of such paradigms would require cribriform morphology to be reported at the time of prostate biopsy, as patients harbouring such a pattern are poor candidates for surveillance. To date, only a limited number of studies have described the molecular alterations that occur in the cribriform morphological pattern. Further refinement of prostate cancer grading paradigms to distinguish cribriform from noncribriform Gleason pattern 4 is essential.

Entities:  

Mesh:

Year:  2018        PMID: 29713007     DOI: 10.1038/s41585-018-0013-1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  9 in total

1.  Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.

Authors:  Jie Gao; Chengwei Zhang; Qing Zhang; Yao Fu; Xiaozhi Zhao; Mengxia Chen; Bing Zhang; Danyan Li; Jiong Shi; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-25       Impact factor: 9.236

2.  Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.

Authors:  Adrian J Waisman Malaret; Peter Chang; Kehao Zhu; Yingye Zheng; Lisa F Newcomb; Menghan Liu; Jesse K McKenney; James D Brooks; Peter Carroll; Atreya Dash; Christopher P Filson; Martin E Gleave; Michael Liss; Frances M Martin; Todd M Morgan; Peter S Nelson; Daniel W Lin; Andrew A Wagner
Journal:  J Urol       Date:  2021-12-02       Impact factor: 7.450

3.  Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.

Authors:  Sigrid Carlsson; Nicole Benfante; Ricardo Alvim; Daniel D Sjoberg; Andrew Vickers; Victor E Reuter; Samson W Fine; Hebert Alberto Vargas; Michal Wiseman; Maha Mamoor; Behfar Ehdaie; Vincent Laudone; Peter Scardino; James Eastham; Karim Touijer
Journal:  J Urol       Date:  2020-01-07       Impact factor: 7.450

4.  Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.

Authors:  Fang Lyu; Yunxue Li; Zhecheng Yan; Qingliu He; Lulin Cheng; Pu Zhang; Bing Liu; Chunyu Liu; Yarong Song; Yifei Xing
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440

5.  Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer.

Authors:  Ahmad Chaddad; Michael J Kucharczyk; Tamim Niazi
Journal:  Cancers (Basel)       Date:  2018-07-28       Impact factor: 6.639

Review 6.  Approaches to urinary detection of prostate cancer.

Authors:  Jillian N Eskra; Daniel Rabizadeh; Christian P Pavlovich; William J Catalona; Jun Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-01-17       Impact factor: 5.554

7.  Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; Ivo Schoots; John Rietbergen; Jozien Helleman; Monique J Roobol; Geert J L H van Leenders
Journal:  Histopathology       Date:  2019-08-02       Impact factor: 5.087

8.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

9.  Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Monique J Roobol; Jozien Helleman; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-04       Impact factor: 5.087

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.